Results 241 to 249 of about 34,864,199 (249)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Dual-trigger model of CD20 escape: NONO regulation and cryptic splicing induced by transcript overload in pediatric B-ALL. [PDF]

Front Immunol
Kermani M, Maxeiner S, Alt F, Ziegler N, König J, Paret C, Faber J.   +6 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Ovarian relapse in a child with B-ALL: a case report. [PDF]

Pan Afr Med J
Cheikhna M, Mahdaoui CE, Guebessi NB, Zeggwagh A, Khoubila N, Lamchahab M, Qachouh M, Rachid M, Madani A, Cherkaoui S.   +9 more
europepmc   +1 more source

The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis. [PDF]

Ther Adv Hematol
Zhou X, Yang J, Fan J, Zhang X, Wang X, Yi H.   +5 more
europepmc   +1 more source

Gene-edited CAR T cells: going the distance in B-ALL. [PDF]

Blood Adv
Ligon JA, Shah NN.
europepmc   +1 more source

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel. [PDF]

Blood Adv
Appell LE, Baggott C, Nguyen K, Prabhu S, Pacenta H, John S, Fabrizio VA, Phillips CL, Rossoff J, Talano JA, Moskop A, Phelan R, Baumeister SHC, Verneris MR, Hall EM, Myers GD, Karras NA, Cooper SL, Qayed M, Raikar SS, Winestone L, Hermiston M, Satwani P, Krupski C, Keating AK, Friedman DN, Curran KJ, Hoover A, MacMillan ML, Ebens CL, Ramgopal A, Rahrig AL, Mackall CL, Laetsch TW, McNerney K, Schultz LM.   +35 more
europepmc   +1 more source

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL. [PDF]

Cell Transplant
Shao X, Zhang M, Qiu H, Yang J, Xia X, Cai Y, Tong Y, Huang C, Dong B, Zhou K, Wan L, Feng Y, Song X.   +12 more
europepmc   +1 more source

Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study. [PDF]

BMC Pediatr
Eghbali A, Nasrabadi ZN, Faranoush M, Ghasemi A, Ghaffari K.   +4 more
europepmc   +1 more source